부산대학교 도서관

Few real‐life studies evaluated long‐term apremilast therapy in the variable spectrum of clinical‐anamnestic features which can be found in psoriatic arthritis (PsA) patients. This real‐life retrospective observational study aimed to assess long‐term efficacy, safety, and tolerability of apremilast among patients with PsA and concomitant cutaneous psoriasis. A stratified analysis was performed on special populations, defined as (a) number (≤1 vs >2) of comorbidities, presence or absence of: (b) history of malignancy, and (c) previous exposure to biologics. Patients attending three Italian University and Hospital centers, who received at least one dose of apremilast and had at least one follow‐up visit were included. Ninety‐six patients with PsA were identified. Psoriasis Area and Severity Index (PASI), Body Surface Area, 28‐joint Disease Activity Score, and Dermatology Life Quality Index scores improved during treatment, already at week 4, relative to baseline. More than 2 comorbidities, history of malignancy and previous biologic treatment negatively influenced PASI responses. At least one adverse event was experienced by 56/96 patients, and 11/56 events required drug withdrawal. In conclusion, this study confirm efficacy and safety of apremilast on joints and skin involvement of PsA, highlighting which patients could have less favorable treatment response. [ABSTRACT FROM AUTHOR]